GT BIOPHARMA, INC. Increase (Decrease) in Interest Payable, Net
GT BIOPHARMA, INC. (GTBP) reported Increase (Decrease) in Interest Payable, Net of $689.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2023-03-30
- GT BIOPHARMA, INC. increase (decrease) in interest payable, net for the quarter ending 2021-12-31 was $0.00.
- GT BIOPHARMA, INC. increase (decrease) in interest payable, net for the quarter ending 2021-09-30 was $0.00.
- GT BIOPHARMA, INC. increase (decrease) in interest payable, net for the quarter ending 2021-06-30 was -$7.00K.
- GT BIOPHARMA, INC. increase (decrease) in interest payable, net for the quarter ending 2021-03-31 was $696.00K.
- GT BIOPHARMA, INC. increase (decrease) in interest payable, net for fiscal 2021 was $689.00K, a 77.03% decline from fiscal 2020.
- GT BIOPHARMA, INC. increase (decrease) in interest payable, net for fiscal 2020 was $3.00M.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | -$7.00K derived: sum of 3 quarters · filed 2023-03-30 | $689.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-31 | -$7.00K derived: sum of 2 quarters · filed 2022-10-31 | $689.00K 10-Q · filed 2022-10-31 | |
| 2021-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $689.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $696.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $3.00M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |